Merck's Lipfendra: 59% LDL Cut with First Oral PCSK9 Pill Approved

For health systems grappling with the burden of uncontrolled LDL cholesterol, Merck's oral PCSK9 inhibitor could be a game-changer. With LDL reductions of up to 59%, Lipfendra offers a pill-based option that may overcome adherence and access barriers that have limited injectable therapies to less than 5% of eligible patients.

The FDA approval of Merck’s Lipfendra on July 16, 2026 marks a watershed moment in cardiovascular medicine, introducing the first oral PCSK9 inhibitor—a class previously limited to expensive injectable biologics. The agency cleared the once-daily pill for high-risk patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia whose LDL cholesterol remains uncontrolled despite maximally tolerated statins. By blocking the PCSK9 protein, which normally restricts the liver’s ability to clear LDL from the blood, Lipfendra delivers efficacy comparable to existing injectables while eliminating the need for self-injection and cold-chain storage.

“

With LDL reductions of up to 59%, Lipfendra offers a pill-based option that may overcome adherence and access barriers that have limited injectable therapies to less than 5% of eligible patients.

In the pivotal Phase 3 trial of 3,000 patients, those adding Lipfendra to their statin therapy saw LDL cholesterol plunge more than 55% after six months. A second study showed a mean reduction of 59% versus placebo, with benefits sustained over one year and a side-effect profile indistinguishable from placebo—only mild dizziness and diarrhea were noted. The single caveat is that the pill must be taken on an empty stomach, a minor but clinically relevant adherence factor. These data position Lipfendra as a potent add-on therapy for the estimated 30% of statin-treated patients who fail to reach LDL targets, a group that has historically been underserved by available oral agents like ezetimibe.

For more than a decade, injectable PCSK9 inhibitors from Amgen (Repatha) and Regeneron/Sanofi (Praluent) demonstrated similar LDL reductions, yet their uptake was stymied by high annual costs exceeding $5,000, cumbersome prior authorization requirements, and patient aversion to injections. As a result, utilization has hovered below 5% of eligible patients. Lipfendra’s oral format directly addresses these barriers and could expand the market dramatically. Merck’s pill is poised to shift treatment paradigms: primary care physicians, who manage most cholesterol patients, are far more likely to prescribe a pill than an injectable, potentially driving early add-on therapy before end-organ damage occurs.

The approval also highlights an intriguing regulatory subplot. The expedited review pathway used by the FDA was originally championed by former Commissioner Dr. Marty Makary, who resigned in May 2026 amid political pressure. Despite his departure, the pathway delivered its highest-profile approval to date, validating its purpose and raising questions about whether future commissioners will maintain the accelerated framework. For Merck, the fast-track decision shortens the time to market just as Novartis abandoned its own oral PCSK9 program, leaving the field wide open.